Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ENANTA PHARMACEUTICALS INC (ENTA)

Enanta CEO Jay Luly to retire by February 1, 2027; Tara Kieffer named COO

Neutral Impact 4 of 5 leadership Written later

Enanta Pharmaceuticals said CEO Jay R. Luly, Ph.D., 70, will retire by February 1, 2027, after 23 years leading the company, and will serve as a strategic advisor for the rest of 2027. The board has started a search for a successor, considering both internal and external candidates, and named Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer. The filing does not include financial results, so the changes are mainly about management succession for shareholders.

Key points

  • Jay R. Luly, Ph.D., age 70, will retire as President and CEO by February 1, 2027, after 23 years with the company
  • Luly will continue as a strategic advisor for the remainder of 2027; the company expects to enter an agreement for this role
  • The board is searching for a successor, considering internal and external candidates
  • Tara L. Kieffer, Ph.D., age 48, was appointed Chief Operating Officer on October 28, 2026; she joined Enanta in 2020 as Chief Product Strategy Officer

The filing

CompanyENANTA PHARMACEUTICALS INC (ENTA)
Form8-K, current report
Filed with the SECOct 28, 2026, 7:14 AM ET
Accession number0001193125-26-435092

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.